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OBJECTIVES: To describe patterns of resource con-
sumption and costs associated with the management of
metabolic abnormalities (MA) among newly diagnosed
HIV+ patients compared to a matched cohort of non-
infected individuals. METHODS: This was a one-year
retrospective database study. Administrative claims from
a managed care organization located in the Western US
were used. Patients 18+ years with a single inpatient or 2
outpatient medical claims with HIV-related ICD-9 codes
(042–044, 079.53, 795.71, V08) or at least 2 pharmacy
claims for antiretroviral therapy for >30 days between
July 1999 and June 2000 were eligible. Patients with
claims for HIV or MA prior to index date were excluded.
In addition, a matched control cohort was identiﬁed.
Patients were matched 3 :1 based on age, gender and
state. Outcomes were MA-related prescriptions, ER visits,
physician ofﬁce visits, hospitalizations, and associated
costs. Statistical analysis was conducted using chi-square
or t-test as appropriate. RESULTS: One thousand three
hundred sixty-eight controls and 456 HIV+ patients were
eligible. Mean age was 40 years, and 86% were males.
The HIV+ patients had a higher Charlson Comorbidity
Index of 0.46 vs. 0.05 (p = 0.0001). More HIV+ patients
had a physician visit (12.5% vs. 10.7%; p = NS), hospi-
talization (2.6% vs. 0.9%; p = 0.004), and ER visit (2.2%
vs. 0.1%; p < 0.0001) for MA. Odds ratio for MA-related
hospitalizations and ER visits in the HIV vs. control
cohorts were 3.1 (95% CI: 1.4–6.8) and 15.3 (95% CI:
3.3–70.2), respectively. Population level mean medical
(physician visits, ER visits, hospitalizations) and phar-
macy costs for MA in the HIV+ vs. control cohorts were
$473.93 vs. $128.60 (p = 0.03); $42.80 vs. $13.69 (p =
0.0005), respectively. CONCLUSIONS: The one-year
resource consumption and costs related to MA were sig-
niﬁcantly higher among the HIV+ cohort. The occurrence
of MA in HIV+ patients was associated with a higher
burden than in control patients with the greatest impact
on MA-related hospitalization and ER visits.
PIN40
THE COST EFFECTIVENESS OF IMPROVED
ADHERENCE TO ANTIRETROVIRAL TREATMENT
Zaric GS1, Bayoumi AM2, Brandeau ML3, Owens DK4
1University of Western Ontario, London, ON, Canada; 2St.
Michael’s Hospital and University of Toronto,Toronto, ON,
Canada; 3Stanford University, Stanford, CA, USA; 4VA Palo
Alto Health Care System and Stanford University, Palo Alto,
CA, USA
OBJECTIVES: We investigate the cost effectiveness of
counseling to improve adherence to highly active anti-
retroviral therapy (HAART) regimens for HIV infection.
Low adherence may lead to drug-resistant HIV strains
and poor health outcomes. METHODS: We develop a
dynamic compartmental model of HIV progression that
accounts for multiple treatment regimens (three HAART
regimens followed by salvage therapy), four levels of
resistance to HAART, and three levels of adherence 
to HAART (high, low, and very low). We assume that
61% of high-adherence individuals remain in the high-
adherence state at the end of each year. We assume a
counseling session by a trained pharmacist is given upon
initiation of HAART and following all treatment failures
(deﬁned as viral load rebound). We assume that such
counseling costs $100 per session, and increases retention
in the high-adherence state. We evaluate the cost effec-
tiveness of counseling by simulating over a ten-year time
horizon. RESULTS: If the counseling sessions increase
retention in the high-adherence state to 65%, then coun-
seling costs $83,700 per QALY gained; if they increases
the rate to 75%, then counseling costs $19,500 per QALY
gained. If the rate at which individuals switch from low
to high adherence in the absence of any interventions is
greater than 10% per year then the cost effectiveness of
counseling is relatively insensitive to the improvement in
adherence. The cost effectiveness of improved adherence
is very sensitive to changes in the cost of the counseling
sessions. CONCLUSIONS: Counseling to improve adher-
ence to HAART is likely to be cost effective if it increases
the high-adherence retention to at least 75% per year.
Additional empirical studies are needed to determine the
effectiveness of other methods of improving adherence,
such as electronic reminders and directly observed
therapy. The dangers posed by drug-resistant HIV strains
makes this an important issue for further study.
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OBJECTIVES: Despite frequently causing serious illness
in adolescents, immunization programmes against per-
tussis have been restricted to children <7. We estimated
the economic impact of introducing a booster dose of
acellular pertussis vaccine in two Canadian provinces
(Ontario and Québec) using different vaccination sched-
ules. METHODS: We conducted a cost effectiveness
analysis using a predictive spreadsheet model with ado-
lescents aged 12 (cohorts of 88,000 in Québec and
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144,000 in Ontario) over a 10-year horizon, from provin-
cial Ministry of Health (MoH) and societal perspectives.
For Québec, costs and beneﬁts of adding acellular per-
tussis to combined diphtheria-tetanus vaccine (DacPT) in
schools were compared to the current practice of admin-
istering the diphtheria-tetanus vaccine only. In Ontario,
we assumed co-administration of the new vaccine with
Hepatitis B vaccine. Efﬁcacy and utilisation data (vacci-
nation, management of pertussis infection and hospital-
ization) were derived from the literature. Productivity 
loss of parents and older adolescents was estimated. 
Standard cost lists were used (CAD$), discounted at 3%.
RESULTS: From the MoH perspective, the expected addi-
tional cost of DacPT per adolescent over 10 years was
$5.80 for Québec and $3.19 for Ontario; the respective
expected incremental cost-effectiveness ratios were
$184.83 and $101.73 per pertussis case avoided. From
the societal perspective, the additional 10-year cost would
be $2.70/adolescent with an expected incremental cost-
effectiveness ratio of $86.03 per case avoided in Québec,
while in Ontario there would be savings of $6.67 per 
adolescent. In Québec, more than 2760 pertussis cases
would be prevented, and 4520 in Ontario. CONCLU-
SION: This study suggests that administering a booster
dose of DacPT at age 12, may reduce the burden of per-
tussis at a reasonable cost, potentially with savings to
society. The impact of implementing the new programme
is lower in Ontario, as it assumes additional savings by
shifting administration of the vaccine from the physician
to the school.
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OBJECTIVE: To assess the cost of varicella infections in
Poland from payers and societal perspectives as a part of
evaluation of cost-effectiveness of varicella vaccination.
Background: Mass vaccination against varicella is pos-
sible as safe, effective, and providing life-long protection
vaccine (Varilrix) became available and the possibility
that vaccination would shift varicella infections to older
age groups seems remote. METHODS: We collected data
of medical and non-medical resources used by patients
suffering from varicella. Medical costs were taken from
local health services price lists and retail prices of drugs
were used. All local prices were changes into dollars. 
Epidemiological data were taken from national health
statistics data for 2000: incidence 331.3/100,000, preva-
lence 12,8016, hospitalisations 1008 and 2 deaths. Main
assumptions (based on experts panel): 2 doctors visits,
antihistaminics, analgesics, antipyretic, antiviral, and
antibiotics, and 4 days loss of productivity—all for one
case. RESULTS: Direct cost per case accounted to 49.12
USD and indirect cost per case, to 91.64 USD. Total cost
per case was: 140.76 USD. Total annual cost per popu-
lation was 11,050,867 USD with 5,771,872 USD of
direct costs and 5,278,995.7 USD of indirect costs.
CONCLUSION: Varicella has considerable burden on
Polish health care system. As safe and long-term 
effective vaccine against varicella is available in Poland,
cost-effectiveness and cost-beneﬁt analyses will be 
performed.
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OBJECTIVES: Even though inﬂuenza vaccinations have
been shown to decrease morbidity, mortality, and hospi-
talization costs among seniors in the United States, vac-
cination rates among seniors remain below national
standards. Positive health perceptions may decrease
immunization seeking behavior, and indirectly increase
medical expenditures. This analysis investigates the main
effect of immunization status as well as the interaction
between health perception and immunization status on
total medical expenditures in the elderly. METHODS:
Participants included 1350 individuals aged 65 and older
with non-zero total medical expenditures who responded
to the 1996 University of Michigan Health Retirement
Survey (HRS) survey. Total medical expenditures were
measured as out-of-pocket or insurance spent between
1994 and 1996. Positive vaccination status was assigned
to individuals who self-reported receiving an inﬂuenza
shot between 1994 and 1996. Ordinary Least Squares
(OLS) was used to estimate medical expenditures in the
ﬁnal multivariate model. RESULTS: The vaccinated
elderly population had on average 35% higher total
medical expenditures than the non-vaccinated popula-
tion, after controlling for perceived health status, func-
tional limitations, age, gender, race, income, education,
and marital status. Self-reported health status did not
modify the association between vaccination status and
medical expenditures (F(4,1302) = 1.40, p = 0.2319).
CONCLUSIONS: Immunized seniors spend more on
medical care than non-immunized seniors, suggesting that
seniors seeking immunizations utilize the health system
more frequently. Perceived health status was not found to
be an effect modiﬁer, suggesting that the association
between a senior’s immunization status and their medical
costs is independent of how they perceive their own
health. Since this cross-sectional analysis has limitations
in drawing conclusions of the effect of immunizations 
on medical expenditures, future studies need to employ 
longitudinal analysis to further investigate the role of 
perceived health status among non-vaccinated elder 
populations. Understanding this role will contribute to
